TGFB2 and glioblastoma: The KM survival analysis results showed that patients with high expression levels of TGFβ1, TGFβ2 and TGFβ3 (GBM, LUSC, TGCT, SARC, BLCA, PAAD, KIRP, LIHC, MESO, COAD, THCA, HNSC, READ, LGG, ACC and UVM) had a shorter survival (Figure 1F).